New Key Statistics Module, Z-Score and F-Score
TSX:NVLN Key Ratios
| Market Cap C$ M | 247.12 |
| Enterprise Value C$ M | 247.12 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | -- |
| Price/Sales | -- |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) C$ M | 179.00 |
| EPS (TTM) C$ | -3.91 |
| Beneish M-Score | 0 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -- |
| EV-to-EBITDA | -- |
| PEG | -- |
| Shares Outstanding M | 18.93 |
| Net Margin (%) | -- |
| Operating Margin % | -- |
| Pre-tax Margin (%) | -- |
| Quick Ratio | -- |
| Current Ratio | -- |
| ROA % (ttm) | -- |
| ROE % (ttm) | -- |
| ROIC % (ttm) | -- |
| Dividend Yield % | -- |
| Altman Z-Score | -- |
TSX:NVLN Number of Guru Trades
TSX:NVLN Volume of Guru Trades
Gurus Latest Trades with TSX:NVLN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
TSX:NVLN is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Novelion Therapeutics Inc Insider Transactions
No Available Data
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers